Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Elritercept Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Elritercept: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Namodenoson Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Namodenoson: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Ifebemtinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Ifebemtinib: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Licaminlimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Licaminlimab: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Avitinib Maleate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Avitinib Maleate: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Lestaurtinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Lestaurtinib: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Sotiburafusp alfa Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Sotiburafusp alfa: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Atirmociclib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Atirmociclib: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Torsemide/Spironolactone Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Torsemide/Spironolactone: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Drotokibart Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
Drotokibart: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
APSMNF Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
APSMNF: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
N-1-methylnicotinamide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
23 July 2026
N-1-methylnicotinamide: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.